Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1215-2022Class II

BD Anti-Kappa PE (Cat. No. 346587) is an analyte specific reagent for the Anti-Kappa antibody, which...

Becton, Dickinson and Company, BD Biosciences / initiated 2022-03-25 / Open, Classified / root cause: manufacturing process

Becton, Dickinson and Company, BD Biosciences began a recall of BD Anti-Kappa PE (Cat. No. 346587) is an analyte specific reagent for the Anti-Kappa antibody, which specifically recognizes the kappa light chains of human... on . FDA classified it as Class II and gives the reason as "Anti-Kappa APC & Anti-Kappa PE analyte reagents may exhibit uncharacteristic flow profiles". As of , the recall status on record is Open, Classified, and MDM tags the root cause as manufacturing process.

Recall record

Recall number
Z-1215-2022
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
Becton, Dickinson and Company, BD Biosciences
Product
BD Anti-Kappa PE (Cat. No. 346587) is an analyte specific reagent for the Anti-Kappa antibody, which specifically recognizes the kappa light chains of human immunoglobulins. Anti-Kappa is used for in vitro identification of cells expressing the kappa light chains using flow cytometry.
Product code
MVU Reagents, Specific, Analyte
Reason for recall
Anti-Kappa APC & Anti-Kappa PE analyte reagents may exhibit uncharacteristic flow profiles.
Root cause tag
manufacturing process
FDA root cause
Process control
Action
On April 20, 2022, BD Biosciences issued a "Urgent Product Recall" notification via FeDEx to affected consignees. The firm ask consignees to take the following actions: 1. Immediately review your inventory for the specific Catalog and lot numbers listed above. Destroy all product subject to the recall following your institution s process for destruction. 2. Share this recall notification with all users of the product within your facility to ensure that they are also aware of this recall. 3. If the product was used in LDTs to generate patient results, please also review potential impact to patient results following your institution s policies. 4. Complete the attached Customer Response Form and return to the BD contact noted on the form. Even if you do not have any of the affected lots in your inventory, please complete the Customer Recall Response Form indicating you have zero (0) quantity and return as indicated. 5. Report any adverse health consequences experienced with the use of this product to BD. Events may also be reported to the FDA's MedWatch Adverse Event Reporting program via the: Web: MedWatch website at www.fda.gov/medwatch Phone: 1-800-FDA-1088 (1-800-332-1088) or Mail: MedWatch, HF-2, FDA, 5600 Fisher s Lane, Rockville, MD 20852-9787
Quantity in commerce
199 units
Distribution
Worldwide distribution - US Nationwide distribution in the states of AL, CA, CO, DC, DE, FL, IA, IL, IN, LA, MA, MD, ME, MI, MN, MO, NC, ND, NY, OH, OK, PA, TN, TX, UT, VA, WA, WI, WV and the country of Taiwan.
Product codes and lots
Lot # 1228977; UDI: 00382903465873

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1215-2022
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1214-2022Class IIOngoingVoluntary: Firm initiated
Z-1215-2022Class IIOngoingVoluntary: Firm initiated